Article info
PDFOriginal research
Familial disclosure by genetic healthcare professionals: a useful but sparingly used legal provision in France
- Correspondence to Dr Benjamin Derbez, Universite de Bretagne Occidentale Faculte de Medecine et des Sciences de la Sante de Brest, Brest 29238, France; benjamin.derbez{at}univ-brest.fr
Citation
Familial disclosure by genetic healthcare professionals: a useful but sparingly used legal provision in France
Publication history
- Received October 15, 2018
- Revised June 17, 2019
- Accepted August 3, 2019
- First published August 28, 2019.
Online issue publication
December 03, 2019
Article Versions
- Previous version (28 August 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- An evaluation of needs of female BRCA1and BRCA2 carriers undergoing genetic counselling
- Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol
- Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium
- From proband to provider: is there an obligation to inform genetic relatives of actionable risks discovered through direct-to-consumer genetic testing?
- Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations
- Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK
- The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation
- Care of men with cancer-predisposing BRCA variants
- Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer
- Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations